Asthma is a chronic respiratory disease that affects more than 25 million people in the US. Asthma generally causes swelling of your airways, making it harder to breathe and causing symptoms like coughing.

However, there are many different types of asthma, like allergic or occupational asthma, that can have a variety of symptoms. Finding out which type of asthma you have can help you figure out the best way to treat it.

Here is what you need to know about the different types of asthma and how each is treated.

Allergic asthma is the most common type of asthma, and affects about 60% of asthmatics in the US. If you have allergic asthma, your symptoms, like coughing or struggling to breathe, are triggered when you breathe in allergens.

Some of the most common allergens are:

When you are exposed to these triggers, your immune system interprets them as harmful invaders and releases antibodies that cause your airway to swell up and become narrower, making it harder for you to breathe.

Your doctor can determine what allergen triggers your symptoms by doing blood or skin tests. If you have allergic asthma, you will need to avoid allergy triggers and you may need to take a prescription medicationlike Montelukast (Singulair), which helps decrease the inflammatory response that tightens airways.

Your doctor may also suggest allergy shots, which slowly introduce small amounts of an allergen into your body so that you gradually build up a tolerance. You may also need an albuterol rescue inhaler, which can quickly open your airway during an asthma attack.

Exercise-induced asthma is a more mild form of asthma in which your symptoms only arise after exercising.

"Symptoms do not start during exercise when the airways are dilated, but rather 10-15 minutes after when adrenaline levels, which help dilate the airways, come down," says Arjan Flora, MD, a professor of pulmonology at the University of Cincinnati.

You are most likely to have asthma symptoms like chest tightness or wheezing after exercising in cold, dry air, since it can make your airways swell and constrict.

According to Flora, the best ways to prevent exercise-induced asthma are:

And be sure to always carry an inhaler when you know you are going to be working out.

If you have cough-variant asthma, your main asthma symptom is a persistent dry cough. It's typical not to have other asthma symptoms like shortness of breath or wheezing.

"Treatment for cough variant asthma is largely the same as for regular asthma, using the same medications," says Neil Schachter, MD, a professor of pulmonary medicine at the Icahn School of Medicine at Mount Sinai.

This includes daily corticosteroid inhalers like budesonide (Rhinocort) and flucytosine (Flovent) to reduce swelling in your airways and an albuterol rescue inhaler for flare-ups.

"However, the most important feature of treatment is making sure that the diagnosis is correct," Schachter says. This is because other conditions like hay fever or acid reflux can also cause a chronic cough. Discussing your symptoms with your doctor can help rule out other possible conditions.

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that prevents your airways from expanding properly, leaving some air trapped inside your lungs when you exhale. COPD symptoms usually begin in middle age and the main symptoms are shortness of breath, coughing, and excess phlegm.

If you have asthma-COPD overlap (ACO), you may exhibit all the symptoms of COPD along with typical asthma symptoms like wheezing and chest pain. ACO can cause attacks that are especially severe and can lead to hospitalization.

The most common cause of COPD is exposure to cigarette smoke, though some people may develop the condition after long-term exposure to irritating gases or fumes like car exhaust. By the time your symptoms appear, "the lungs are frequently damaged beyond repair," says Schachter. This means that while you can get your symptoms under control, you generally can't stop the disease from progressing.

Though ACO can be more serious than asthma, "in many ways the treatment is the same," Schachter says. This can include taking a long-acting airway opener like Singulair, a corticosteroid inhaler like Pulmicort, and an albuterol rescue inhaler for attacks. You may also need to add on additional medication to prevent mucus build-up.

Occupational asthma occurs when you develop asthma symptoms after being exposed to irritating substances like chemical fumes, animal waste, or smoke in your workplace. There have been over 250 different agents identified that can trigger occupational asthma.

Occupational asthma develops when you regularly inhale substances that can irritate your lungs, which leads to swelling of your airways and difficulty breathing. This irritation can be caused by an allergen, like animal dander or plant substances, or a universally irritating substance, like chlorine gas, chemicals in detergents, or metals like platinum.

According to Flora, some of the most high-risk jobs for exposure to allergens are:

The most high-risk jobs that may expose you to general lung irritants are:

The best way to prevent and treat occupational asthma is for companies to provide protective gear and train workers to safely handle irritants. Under the Occupational Safety and Health Administration (OSHA) guidelines, your employer is legally required to offer you these protections. You can also meet with your doctor to come up with an individual safety plan and get standard asthma medications.

Nocturnal asthma occurs when your asthma symptoms get significantly worse at night. Nocturnal asthma is common and can happen along with any type of asthma, including allergic or non-allergic.

The symptoms of nocturnal asthma are the same as regular, daytime asthma, but you may also experience symptoms like daytime sleepiness and frequent waking in the night. This is because frequent bouts of nocturnal asthma can interfere with your natural sleep schedule and lower the quality of your sleep.

Experts aren't sure why asthma symptoms can become worse at night, but one factor may be your hormones. In particular, levels of a hormone called histamine can spike while you are asleep , which can lead to swelling of your airways and awaken you from sleep.

"Additional complicating factors include dust mites and pet dander which can be in bed sheets, pillows, and mattresses," says Flora. So if you have allergic asthma, you may need to wash your bedding more often and keep pets out of the bedroom to fight off nighttime symptoms.

Non-allergic asthma occurs when your asthma symptoms are triggered by factors unrelated to allergens like pollen and dust. Non-allergic asthma generally starts later in life most people over 40 who develop asthma for the first time will have non-allergic triggers.

Experts are not certain why non-allergic asthma develops, but having repeated infections in your airway like bronchitis can increase your risk of non-allergic asthma, Flora says.

There are many possible triggers for non-allergic asthma, including:

The symptoms of non-allergic asthma are essentially the same as allergic asthma, including chest tightness, coughing, and difficulty breathing. After having an allergist rule out the possibility of an allergy, your doctor may work with you to identify your triggers. The treatment is also similar to allergic asthma, using long-term preventative medications and fast-relief inhalers.

If you find yourself having asthma symptoms, it's important to meet with a doctor as soon as possible to help get your symptoms under control.

Monitoring your own symptoms can also help out with diagnosis, Flora says. "Keeping a diary of onset of symptomatic episodes with potential triggers/exposures, time of day, location (ie work, outdoors), and the presence of other medical conditions can help you and your doctor discover what type of asthma you have and how you may prevent symptoms from occurring."

See the original post:
7 types of asthma and how to treat each one - Insider - INSIDER

Recommendation and review posted by Bethany Smith

CARLSBAD, Calif., Aug. 20, 2020 /PRNewswire/ --Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the United States Patent and Trademark Office has issued patent No. 10,744,257 entitled "Devices and Methods for On-Line Whole Blood Treatment" regarding the Company's Selective Target Antigen Removal System (STARS) technology.

STARS is a DNA/RNA-based treatment device candidate for the removal of viral and tumor-produced compounds from a patient's blood. The STARS technology utilizes a filtration cartridge designed for use in a standard dialysis machine, and contains aptamer-coated microparticles that bind to specific agents in circulating blood for targeted removal.

"This patent strengthens our intellectual property portfolio and increases our number of issued patents to 26, or 45 including jointly held patents. Our strategy is to continue to protect our proprietary technologies in the U.S. and globally," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen. "Although STARS is in the early stages of development, our in vitro studies have demonstrated encouraging proof-of-concept results and we look forward to advancing this program as a target-and-removal therapy for a broad range of diseases."

The STARS development program utilizes technology and expertise from the Company's FastPack point-of-care diagnostic system, which has been in use worldwide for nearly 20 years for the detection of cancer and other diseases. The Company plans to develop STARS for cancer applications to remove inflammatory factors and inhibitory checkpoints from blood, thus reducing pain and helping the body's immune system fight the disease, as well as for infectious diseases to remove viruses and other foreign agents.

About Qualigen Therapeutics, Inc.Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes' proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Because Qualigen's therapeutic candidates are still in the development stage, Qualigen's only products that are currently commercially available are FastPack System diagnostic instruments and test kits, used in physician offices, clinics and small hospitals around the world. The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men's health, hormone function, vitamin D status and antibodies against SARS-CoV-2. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/.

Forward-Looking StatementsThis news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's intellectual property protection intentions and potential future development, testing and launch of STARS and other product candidates. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company's drugs or therapeutic devices will be successful; that clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that patents will issue on the Company's in-licensed patent applications; that such patents, if any, and the Company's current owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products; that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products generally, particularly in view of COVID-19-related deferral of patients' physician-office visits and FastPack reimbursement pricing challenges; that adoption and placement of FastPack PRO System instruments (which are the only FastPackinstruments on which the Company's SARS-CoV-2 IgGtest kits can be run) will be widespread; that the Company will be able to manufacture the FastPack PRO System instruments and SARS-CoV-2 IgGtest kits successfully; that any commercialization of the FastPack PRO System instruments and SARS-CoV-2 IgGtest kits will be profitable; or that the FDA will ultimately approve an Emergency Use Authorization for the Company's SARS-CoV-2 IgG test. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available atwww.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Qualigen Therapeutics, Inc.

Home

Read more:
Qualigen Therapeutics Announces Issuance of STARS Technology Patent by the US Patent and Trademark Office - PRNewswire

Recommendation and review posted by Bethany Smith

LOS ANGELES For Adam Winney, a 26-year old with Type 1 diabetes, grocery shopping during the early days of a pandemic was an infuriating task. Everything was sold out, except for the one type of food he couldnt eat.

The only things left were carbs, carbs, carbs, the Van Nuys resident said. Ive never been more furious than back in March.

Winneys disease has deprived his body of insulin, a hormone thats needed to turn the sugar in carbohydrates into energy. Without it, his blood sugar can spike to dangerous levels, eventually leading to serious health problems like cardiovascular disease, nerve damage and kidney failure.

But the insulin pens he relies on to keep his body in balance cost him upwards of $1,000 a month, since his health insurance doesnt cover the medication.

After the coronavirus outbreak cost him his job as a receptionist at a hair salon, that expense was beyond his reach. He went six weeks without the long-acting insulin he usually takes every day.

COVID-19 presents a unique set of challenges to the roughly 34 million Americans like Winney who are living with diabetes.

The Centers for Disease Control and Prevention says people with Type 1 diabetes are probably more susceptible to a severe case of COVID-19. Those with Type 2 diabetes the more common form that begins when people lose their sensitivity to insulin are definitely at increased risk of severe COVID-19, according to the CDC.

For instance, a study of more than 7,300 COVID-19 patients in China found that those with Type 2 diabetes needed more medical care and were nearly 50% more likely to die than patients without diabetes.

The risk of death was especially high for people who had trouble controlling their blood sugar, researchers reported. Another study of more than 1,200 COVID-19 patients in the U.S. found that the mortality rate for those with diabetes or high blood sugar was 29%, compared with 6% for those without diabetes.

The extent to which you control your diabetes is a risk factor, said Dr. Daniel Drucker, a senior scientist at the Lunenfeld-Tanenbaum Research Institute at the University of Toronto. Theres a lot we can do about that, by making sure that your diabetes is optimally controlled.

Insulin is essential for keeping blood sugar in check, but the pricey medicine is harder to get if a job disappears, along with the health insurance that came with it.

The cost of insulin varies from patient to patient. It depends on the type of insulin they need some take effect within 15 minutes; others last more than a day _ as well as the dose. Some insurance plans pick up more of the tab than others.

The financial strain brought on by the pandemic has forced Royce Jonathan Miller of Yuba City to consider rationing the insulin he takes for Type 1 diabetes. He has kept his job as an optician at Walmart, but since his father-in-law lost his job at a maintenance company that closed operations due to the pandemic, Miller has become the sole provider for the four people in his household.

Miller has an insulin pump, which uses a tube to continuously deliver a small amount of insulin directly to the pancreas. He is supposed to change out the pieces that connect to his body every three days. Lately, hes been wondering if thats absolutely necessary.

Im starting to think, I can stretch that up for two cycles, every six days, and hopefully it doesnt get infected, Miller said. But I do realize that if I am to make myself sick and wind up in the hospital, that will be a bigger burden.

A nationwide survey of 5,000 people with diabetes conducted for the American Diabetes Assn. found that one in four have rationed supplies to cut the cost of their diabetes care since the start of the pandemic.

Now is not the time to let up on helping these individuals manage their disease, because it may in fact be helpful in preventing them from getting severe COVID-19, Drucker said.

People with Type 2 diabetes may face even greater hardship in affording their insulin, said Dr. Francisco Prieto, a family health physician in Sacramento.

Not everyone who has Type 2 has to take insulin, Prieto said. Those who do are typically folks who either have the most severe cases of diabetes or have failed all the previous oral and injectable treatments. That means they may need to take even more insulin on a daily basis than Type 1 patients, he said.

Since 2019, 11 states have set limits on the amount insurance companies can set as co-payments for insulin. Each of those states has enacted price caps ranging from $25 to $100 per month since the coronavirus outbreak took off in March.

California may soon join the list. In February, Assemblyman Adrin Nazarian, D-North Hollywood, introduced a bill that would cap insulin copays at $50 for a 30-day supply, or $100 per month. It passed in June by a 64-4-11 vote, but the Senate Health Committee has not scheduled a hearing that would allow the bill to move forward.

Winney said a price cap would give him some peace of mind. These days he relies on free samples provided by one of his doctors, but that generosity may not last.

I see that as an incentive to finally change insurance, he said.

Ensuring an affordable supply of insulin would help people with diabetes manage their disease better, said Brandi DaVeiga, a stay-at-home mom in Lakewood with Type 1 diabetes. She has good coverage now through her husbands health insurance plan, but when she was between plans three years ago, she began skipping insulin doses to make her supply last longer. On several occasions, her blood sugar levels rose dangerously high, and she ended up in the emergency room.

Its really stressful, she said of managing diabetes during a pandemic. And that doesnt help your blood sugar.

The fact that people with diabetes are rationing their insulin when they need it most points to larger problems with health care access in this country, Drucker said.

COVID-19 is reminding us of the importance of doing everything we can in our vulnerable, at-risk populations, he said. Lets do everything we can to optimize their health because that may, in turn, reduce their risk of having a bad outcome with this virus.

Here is the original post:
Amid COVID-19 pandemic, people with diabetes struggle to get insulin - Press of Atlantic City

Recommendation and review posted by Bethany Smith

Global CRISPR And CRISPR-Associated Genes Market Professional Survey Report Segmented by Types, Share, Application and Forecast to 2026

The global CRISPR And CRISPR-Associated Genes market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. It focuses on CRISPR And CRISPR-Associated Genes volume and value at global level, regional company level. From a global perspective, this report represents overall CRISPR And CRISPR-Associated Genes market size by analyzing historical data and future prospect.

CRISPR And CRISPR-Associated GenesIndustry Report provides an in-depth and professional study on the current state of the CRISPR And CRISPR-Associated Genes global industry. The research report further categorizes the global CRISPR And CRISPR-Associated Genes market by key regions, top players and market segments. It bifurcates the global CRISPR And CRISPR-Associated Genes market into different geographic segments to show organic growth across the globe including in the emerging economies.

This report also studies the global CRISPR And CRISPR-Associated Genes market status, market share, growth rate, market drivers, opportunities and challenges, future trends, competition landscape, sales channels and distributors.

To Get The Sample Copy https://www.reportsandmarkets.com/sample-request/global-crispr-and-crispr-associated-genes-market-size-status-and-forecast-2020-2026?utm_source=thedailychronicle&utm_medium=15

Prominent Players Leads the Global Industry Growth areThermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics, Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, and Origene Technologies

Market Dynamic

To understand the trajectory of the CRISPR And CRISPR-Associated Genes market, the report keeps track of several key metrics. This document includes microeconomic and macroeconomic factors, which have the potential to lead or hamper the growth of this industry. Similarly, analysts have taken extra steps to record the demographic changes which will take place during the forecast period 2020 2026. In order to achieve high levels of comprehensibility, the report segments the CRISPR And CRISPR-Associated Genes market. As a result it is easier to understand where the industry stands to gain. The report also makes a point to highlight the areas which can experience immense growth during 2020 2026.

Market Segmentation

As the goal is to provide in-depth information, there is segmentation of the CRISPR And CRISPR-Associated Genes marketin the report. The major classifications are region, distribution channel, product type, and application. Distribution channels are the sources companies use in the industry to supply the product/service. Product type refers to the variants of product/service available in the CRISPR And CRISPR-Associated Genes market. Application are the users, such as consumers and industries driving the demand in this line of business.

Regional Overview

Data from various regions is available in this CRISPR And CRISPR-Associated Genes marketreport. The report identifies the area which is the biggest contributor to this industry and compare the data to other countries. Readers will find information from North and South America, Middle East and Africa, Europe, and Asia Pacific. In the report, there is information on which areas will experience immense growth during the forecast period 2020 2026.

Latest Industry News

The last part of the CRISPR And CRISPR-Associated Genes marketreport talks about all the latest advancements taking place in the industry. There is focus on these areas, as they can determine the direction of growth of the CRISPR And CRISPR-Associated Genes market. At the same time, the report covers government policies, both in favor and against the industry. If there are products/services which have the potential to become popular during the forecast period 2020 2026, the report will mention them in the latest industry news.

The study objectives of this report are:To study and forecast the market size of CRISPR And CRISPR-Associated Genes Market in global Industry.To analyze the global key players, SWOT analysis, value and global market share for top players.To define, describe and forecast the market by type, end use and region.To analyze and compare the market status and forecast among global major regions.To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.To identify significant trends and factors driving or inhibiting the market growth.To analyze the opportunities in the market for stakeholders by identifying the high growth segments.To strategically analyze each submarket with respect to individual growth trend and their contribution to the marketTo analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.

Browse the Full Report at @ https://www.reportsandmarkets.com/reports/global-crispr-and-crispr-associated-genes-market-size-status-and-forecast-2020-2026?utm_source=thedailychronicle&utm_medium=15

About us

Market research is the new buzzword in the market, which helps in understanding the market potential of any product in the market. This helps in understanding the market players and the growth forecast of the products and so the company. This is where market research companies come into the picture. Reports And Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world.

Contact Person

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more from the original source:
CRISPR And CRISPR-Associated Genes Market 2020, Research Report Covers Impact of Covid-19, Share, Size, Revenue and Global Industry Growth Forecast to...

Recommendation and review posted by Bethany Smith

IndustryGrowthInsights offers a latest published report on Global CRISPR And CRISPR-Associated (Cas) Genes Market industry analysis and forecast 20192025 delivering key insights and providing a competitive advantage to clients through a detailed report. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report contains XX pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

CRISPR And CRISPR-Associated (Cas) Genes Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the CRISPR And CRISPR-Associated (Cas) Genes global status and trend, market size, share, growth, trends analysis, segment and forecasts from 20192025.

Get FREE Exclusive PDF Sample Copy Of This Report: https://industrygrowthinsights.com/request-sample/?reportId=171631

The scope of the report extends from market scenarios to comparative pricing between major players, cost and profit of the specified market regions. The numerical data is backed up by statistical tools such as SWOT analysis, BCG matrix, SCOT analysis, and PESTLE analysis. The statistics are represented in graphical format for a clear understanding on facts and figures.

Customize Report and Inquiry for The CRISPR And CRISPR-Associated (Cas) Genes Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171631

The generated report is firmly based on primary research, interviews with top executives, news sources and information insiders. Secondary research techniques are implemented for better understanding and clarity for data analysis.

The Report Segments for CRISPR And CRISPR-Associated (Cas) Genes Market Analysis & Forecast 20192025 are as:Global CRISPR And CRISPR-Associated (Cas) Genes Market, by ProductsGenome EditingGenetic engineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering

Global CRISPR And CRISPR-Associated (Cas) Genes Market, by ApplicationsBiotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes

The Major Players Reported in the Market Include:Caribou BiosciencesAddgeneCRISPR THERAPEUTICSMerck KGaAMirus Bio LLCEditas MedicineTakara Bio USAThermo Fisher ScientificHorizon Discovery GroupIntellia TherapeuticsGE Healthcare Dharmacon

The Global CRISPR And CRISPR-Associated (Cas) Genes Market industry Analysis and Forecast 20192025 helps the clients with customized and syndicated reports holding a key importance for professionals entailing data and market analytics. The report also calls for market driven results deriving feasibility studies for client needs. IndustryGrowthInsights ensures qualified and verifiable aspects of market data operating in the real time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real time scenario.

Key Reasons to Purchase:

Ask for Discount on CRISPR And CRISPR-Associated (Cas) Genes Market Report at: https://industrygrowthinsights.com/ask-for-discount/?reportId=171631

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

See the rest here:
CRISPR And CRISPR-Associated (Cas) Genes Market Study Report (2020-2026), Competitive Analysis, Proposal Strategy, Potential Targets, Assessment And...

Recommendation and review posted by Bethany Smith

Crispr Therapeutics AG (CRSP) stock has gained 12.88% over the past week and gets a Bullish rating from InvestorsObserver's Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.

InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.

Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

Crispr Therapeutics AG (CRSP) stock has risen 8.59% while the S&P 500 is unchanged 0% as of 11:17 AM on Wednesday, Aug 19. CRSP is higher by $8.15 from the previous closing price of $94.92 on volume of 1,400,429 shares. Over the past year the S&P 500 has gained 15.68% while CRSP is higher by 112.17%. CRSP earned $0.47 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 221.99.

To screen for more stocks like Crispr Therapeutics AG click here.

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

See original here:
Is Crispr Therapeutics AG (CRSP) a Stock to Watch This Week? - InvestorsObserver

Recommendation and review posted by Bethany Smith

When Kite founder Arie Belldegrun laid out his vision for the new biotech building he and son Dan were building with Tishman Speyer in Seaport, he had an idea for a club-like environment that would bring together scientists and entrepreneurs interested in building drugs and companies.

But then the market took control.

Instead of multiple tenants, Breakthrough Properties got one growing biotech to take all 263,500 square feet of space at The 105.

Once completed in early 2022, the gene editing experts at CRISPR Therapeutics will be moving in to what will now be a custom-built R&D center. CRISPR is a thoroughly global kind of biotech, with its R&D operations in Boston, a corporate headquarters in tax-light Zug, Switzerland and business execs in both London and San Francisco.

The big lease deal along with the news yesterday that Bristol Myers Squibb is taking a big chunk of the Cambridge Crossing development on the line between Cambridge and Somerville, following Sanofi helps underscore how the fast-growing biotech industry has been busting at the seams when it comes to office space in key hubs. And its a clear signal that the development specialists in the field will have some new creations to show off in the not-too-distant future.

The Payette architecture firm did the design work on the building, featuring a fitness facility and outdoor terraces, which is going up alongside the Red Line in the Boston development zone.

Excerpt from:
That new biotech compound Arie Belldegrun & Co. have been building in Seaport? It turns out one fast-growing developer took the whole thing -...

Recommendation and review posted by Bethany Smith

The research, analysis and estimations about the market have been performed with the steadfast knowledge in this Cord Stem Cell Banking Market report. This market report helps to obtain information about all the above factors by giving actionable market insights and comprehensive market analysis. Analysis and discussion of important industry trends, market size, sales volume, and market share are also estimated in this market report. To achieve maximum return on investment (ROI), its very fundamental to figure out market parameters such as brand awareness, market landscape, possible future issues, industry trends & customer behaviour where this Cord Stem Cell Banking Market report comes into picture.

Request for sample copy or PDF Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-cord-stem-cell-banking-market

Global Cord Stem Cell Banking Market report gives clear idea to Healthcare industry in regard with what is already available in the market, what market anticipates, the competitive environment, and what to be get done to surpass the competitor. This market report serves a great purpose of better decision making and achieving competitive advantage. The report supports in evaluating brand awareness, market landscape, possible future issues, industry trends and customer behaviour with which refined business strategies can be fixed. Cord Stem Cell Banking Market report has been comprised of a significant data along with future forecast and detailed analysis on a global and regional level.

Global Cord stem cell banking market is estimated to reach USD 13.8 billion by 2026 registering a healthy CAGR of 22.4%. The increasing number of parents storing their childs cord blood, acceptance of stem cell therapeutics, high applicability of stem cells are key driver to the market.

Few of the major market competitors currently working in the globalcord stem cell banking marketareCBR Systems, Inc., Cordlife, Cells4Life Group LLP, Cryo-Cell International, Inc., Cryo-Save AG, Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS PLUS., Cryoviva India, Global Cord Blood Corporation, National Cord Blood Program, Vita 34, ReeLabs Pvt. Ltd., Regrow Biosciences Pvt. Ltd. , ACROBiosystems., Americord Registry LLC., New York Blood Center, Maze Cord Blood, GoodCell., AABB, Stem Cell Cryobank, New England Cryogenic Center, Inc. among others

Browse Detailed TOC, Tables, Figures, Charts and Companies @https://www.databridgemarketresearch.com/toc?dbmr=global-cord-stem-cell-banking-market

Market Definition: Global Cord Stem Cell Banking Market

Cord stem cells banking is nothing but the storing of the cord blood cell contained in the umbilical cord and placenta of a newborn child. This cord blood contains the stem cells which can be used in future to treat disease such as leukemia, thalassemia, autoimmune diseases, and inherited metabolic disorders, and few others.

Segmentation: Global Cord Stem Cell Banking Market

Cord Stem Cell banking Market : By Storage Type

Cord Stem Cell banking Market : By Product Type

Cord Stem Cell banking Market : By Service Type

Cord Stem Cell banking Market : By Indication

Cord Stem Cell banking Market : By Source

Cord Stem Cell banking Market : By Geography

Key Developments in the Cord Stem Cell banking Market:

Cord Stem Cell banking Market : Drivers

Cord Stem Cell banking Market : Restraint

Scope of the Cord Stem Cell banking Market Report :

The report shields the development activities in the Cord Stem Cell banking Market which includes the status of marketing channels available, and an analysis of the regional export and import. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments. This will benefit the reports users, that evaluates their position in Cord Stem Cell banking market as well as create effective strategies in the near future.

Want Full Report? Enquire Here @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-cord-stem-cell-banking-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Originally posted here:
Cord Stem Cell Banking Market with High CAGR in Coming Years | Global Players Lifecell, StemCyte India Therapeutics Pvt. Ltd, Viacord, SMART CELLS...

Recommendation and review posted by Bethany Smith

This Placental Stem Cells (PSCS) Market report is an outcome of persistent efforts lead by knowledgeable forecasters, innovative analysts and brilliant researchers who carries out detailed and diligent research on different markets, trends and emerging opportunities in the consecutive direction for the business needs. The report also estimates CAGR (compound annual growth rate) values along with its fluctuations for the definite forecast period. The report provides key measurements, status of the manufacturers and is a significant source of direction for the businesses and organizations. While generating this Placental Stem Cells (PSCS) Market research report, customer satisfaction is kept on the utmost priority.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-placental-stem-cells-pscs-market

Placentalstem cells(PSCS) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.25% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of placental derived stem cells will boost the growth of the market.

The major players covered in theplacental stem cells (PSCS) marketreport areCBR Systems, Inc, Cordlife India, Cryo-Cell International, Inc., ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc/?dbmr=global-placental-stem-cells-pscs-market

Key Questions Answered in Global Placental Stem Cells (PSCS) Market Report

Market Analysis and Insights of Global Placental Stem Cells (PSCS) Market

Adoption of advances and novel technologies that will lead to the storage and preservation of stem cells, technological advancement in the field of biotechnology, introduction of hematopoietic stem cell transplantation system and growing number of diseases which will helps in accelerating the growth of the placental stem cells (PSCS) market in the forecast period of 2020-2027. Surging number of applications from emerging economies along with rising awareness among the people will further boost many opportunities that will led to the growth of the placental stem cells (PSCS) market in the above mentioned forecast period.

Increasing operation costs along with stringent regulatory framework will likely to hamper the growth of the placental stem cells (PSCS) market in the above mentioned forecast period. Social and ethical issues will be the biggest challenge in the growth of the market.

Thisplacental stem cells(PSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on placental stem cells (PSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Placental Stem Cells (PSCS) Market Scope and Market Size

Placental stemcells(PSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Placental Stem Cells (PSCS) Market Country Level Analysis

Placental stemcells(PSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The countries covered in the placental stem cells (PSCS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the bone marrow-derived stem cells (BMSCS) market due to the increasing stem cell procedure along with preferences of private stem cell banking over public and surging network of stem cell banking services.

The country section of the placental stem cells (PSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Placental stem cells (PSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for placental stem cells (PSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the placental stem cells (PSCS) market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Placental Stem Cells (PSCS) Market Share Analysis

Placental stem cells (PSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to placental stem cells (PSCS) market.

To Get This Report at an Attractive Cost, Click Herehttps://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-placental-stem-cells-pscs-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Visit link:
Placental Stem Cells (PSCS) Market 2020-2027 Reporting And Evaluation of Recent Industry Developments || Leading Players StemCyte India Therapeutics...

Recommendation and review posted by Bethany Smith

Dr. Johnny Huard will be the Principal Investigator on five-year clinical trial that focuses on Bone Marrow Stem Cell treatments to delay onset of osteoarthritis in the knee

VAIL, Colorado, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health (NIH). SPRI Chief Scientific Officer Johnny Huard, Ph.D. will serve as the principal investigator. Marc J. Philippon, M.D., who serves as managing partner of The Steadman Clinic and co-chair of SPRI and Scott Tashman, Ph.D., director of biomedical engineering at SPRI, will serve as co-principal investigators. The clinical trials are expected to begin enrolling in the Fall of 2020.

The award, administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, ranks as one of the most significant in SPRIs history, both in size and recognition. Given the potential of regenerative medicine to enhance human health and treat disease, the United States Congress included a provision in the 21st Century Cures Act a law passed in December 2016 to accelerate medical discovery and innovation to support the NIH-established Regenerative Medicine Innovation Project (RMIP). The RMIP aims to accelerate the field by supporting clinical research on adult stem cells while promoting the highest standards for protecting patient safety during the conduct of research.

This is a really great honor for SPRI, said Dr. Huard, who first came to Vail in 2015 and has served as the director of the Center for Regenerative Sports Medicine in addition to his role as the institutes chief scientific officer. Past recipients of these RMIP awards have been Albert Einstein College of Medicine, Boston Childrens Hospital, Columbia University Health Sciences, Childrens Hospital of Philadelphia, Harvard University, University of Colorado Denver and Yale University.So, we are in very good company.

The grant anticipates over $2.8 million from the NIH and requires a 1:1 match from SPRI over the next five years, pending availability of federal funds. The clinical trials and resulting publications and reports will take place over the next five years. A generous SPRI benefactor committed to fund the first year of the match, and Dr. Huard is hopeful that with the NIH matching the funds, more philanthropists will be inspired to become involved in this groundbreaking project.

Our donors have been so generous in supporting all that we do here at SPRI, said Dr. Huard, and I am very grateful and confident that we will raise the funds necessary to complete these trials over the next five years.

The trial is entitled,The Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis. Huard explains in laypersons terms:

The idea behind the trial is to delay osteoarthritis in the knee, said Huard. Our goal is to delay the need for that first knee replacement in a patient for as long as we can. Over time SPRI intends to expand this area of research to other joints including hip and shoulder.

This clinical trial is designed to determine whether senolytic and/or antifibrotic agents will improve the beneficial effect of Bone Marrow Stem Cells for the treatment of symptomatic knee osteoarthritis. The trial will include four groups, totaling 100 patients, to investigate the teams hypothesis that the use of these agents will improve patient outcomes.

One of the great things that I love about this particular clinical trial is that we are actively involving our orthopaedic surgeons and our biomotion lab staff as well, said Dr. Huard. This will truly be a team effort over the next five years.

Those world-class surgeons are led by Dr. Philippon, considered one of the worlds foremost orthopaedic surgeons. The biomotion lab is under the direction of Dr. Tashman. The contributions of these two leaders and the talented roster of surgeons, clinicians and technicians in their departments will be critical to the success of the upcoming clinical trials. SPRIs Center for Outcomes-Based Orthopaedic Research and its director Grant Dornan are also participating in this project by contributing the statistical outcomes.

Story continues

Dr. Philippon is not only a world-class surgeon but he is also an innovator, added Dr. Huard. He always wants to improve and is still willing to try new things to enhance patient outcomes. Dr. Tashman is the same way. Like everyone here at SPRI and The Steadman Clinic, they are embracing the cutting-edge technology available to them and finding new and better ways to treat patients and, most importantly, reduce patients recovery time and get them back to their active lives as quickly and safely as possible.

Huard notes that the rare combination of a globally recognized research institute like SPRI and a world-class orthopaedic surgery clinic like The Steadman Clinic in the same building is one of the key factors in the awarding of this RMIP grant.

Weve got something here in Vail that many other research institutes dont have, said Huard. We have one of the worlds finest orthopaedic clinics right next door, working hand-in-hand with us every day.

Dr. Huard and Dr. Tashman along with Suzanne Liv Page, J.D., our director of grants and contracts have worked diligently to prepare and gain acceptance of this grant proposal from the NIH, said Dr. Philippon. Our surgeons here at The Steadman Clinic eagerly await the opportunity to participate in the trial. Johnny, Scott and their staff have put SPRI into position to undertake major trials and studies like this one and we are all very honored that the NIH has given SPRI this incredible opportunity.

For further information or other inquiries about The Steadman Clinic or Steadman Philippon Research Institute, contact Lynda Sampson, Vice President of External Affairs (lsampson@sprivail.org).

Link to current SPRI clinical trials - https://www.sprivail.org/about-us/clinical-trials

Read the original:
Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health - Yahoo Finance

Recommendation and review posted by Bethany Smith

This is paid-for content from our commercial partners.Find out more

So-called scientific breakthroughs are often in the headlines, but in reality, ground-breaking medical innovations adhere to a slow process characterised by cautious clinical experimentation and gradual but continuous improvement before reaching patients. After years of effort, gene therapy looks set to become a routine medical approach to address serious unmet medical need.

Sponsored by

There are two types of gene therapy approved for commercial use today. The first, in vivo, uses a modified virus, administered directly into the body to correct the target cells original genetic defect. The second, ex vivo, takes the patients own cells away from their body for genetic modification with a virus and then puts them back into the patient. Ex vivo gene therapy is dominated by two cell types; CD34+ haematopoietic stem cells (bone marrow stem cells) that can be modified to correct certain genetic disorders, and cytotoxic T-cells that can be altered and trained to kill cancerous cells.

The cell and gene therapy industry in the UK is supported by the formation and growth of many companies with promising assets in clinical development. This thriving biotech community is also supported by a robust and prosperous contingent of specialist manufacturing companies. These companies were key to the recent national covid-19 vaccine manufacturing response because the process for making genetically modified adenovirus such as the SARs-COV-02 vaccine, (as developed at the Oxford University Jenner Institute), is very similar to the process for making viruses for gene therapy.

UK leadership in gene therapy is no accident. As specified in our National Industrial Strategy, the UKs many research councils, in particular the Medicines Research Council, are active in funding the development and translation of treatments. In the UK right now, there are approximately 127 clinical trials testing new cell and gene therapy medicines, which represents 12 per cent of the global total. The government is readying the NHS to support these trials and transition these treatments into more common use through funding of the Advanced Therapy Treatment Centres (ATTC), a multiyear multi-million-pound project coordinated by the Cell and Gene Therapy Catapult and comprising centres of excellence throughout the UK.

In the UK right now, there are approximately 127 clinical trials testing new cell and gene therapy medicines, which represents 12 per cent of the global total. The government is readying the NHS to support these trials

The ATTCs aim to develop and harmonise adoption of the one and done treatment paradigm by developing the appropriate frameworks and systems to support clinical adoption of these novel therapies. The ATTCs and the NHS are also working in partnership to develop novel medicines assessment and reimbursement paradigms which fairly recognise the ultra-long-term medical benefits that can accrue from a one-time gene therapy treatment. Increased adoption of gene therapy, which is proving to be an approach that can reduce the long-term healthcare burden of chronic disease management, has the potential to significantly lighten the NHS resources required for support of several chronic conditions.

As a future example of the UK commitment to gene therapies, we are also leading the practical application of genetic sequencing (genomics). Formation of the National Genomic Test Directory and support for the 100,000 genomes project by Genomics England are critical steps to improve the diagnosis of patients and identification of a new wave of one-off treatments that could be capable of delivering long-term clinical benefit.

Cell and gene therapies are a revolution in medicine and have even been described as the future of the healthcare system. When you consider that 80 per cent of rare diseases have a genetic component, these treatments could transform the prospects of thousands of people living with these conditions, creating a more economically sustainable and brighter future for them and their families.

Go here to read the rest:
A bright future for genomics and gene therapy in the UK - Health Service Journal

Recommendation and review posted by Bethany Smith

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Multiple Studies Suggest Lasting Immunity to COVID-19 After Infection

Although probably not enough time has passed to know definitively, several studies are now suggesting that even mild cases of COVID-19 stimulate lasting immune responses, not only in disease-fighting antibodies, but in B- and T-cells.

Things are really working as theyre supposed to, Deepta Bhattacharya, an immunologist at the University of Arizona, and an author of one of the studies, told The New York Times.

Its difficult, probably impossible, to predict how long those immune responses will last, but many of the researchers believe the results are promising for long-term protection.

This is exactly what you would hope for, Marion Pepper, an immunologist at the University of Washington and an author of a study currently being reviewed by the journal Nature. All the pieces are there to have a totally protective immune response.

Pepper notes that the protective effects cant be completely evaluated until there is proof that people exposed to the virus a second time can fight it off. But the data suggests the immune system is indeed able to fight resistance a second time. Some of this qualification comes from unconfirmed reports of people being reinfected by the virus.

Antibody responses are typically relatively short-lived, disappearing from the blood weeks or months after being produced. Generally, the majority of the B-cells that produce antibodies die off, too. But the body keeps some longer-lived B-cells that are able to manufacture virus-fighting antibodies should the immune system be triggered by re-exposure to the virus. Some stay in the bloodstream while others wait in the bone marrow where they manufacture small numbers of antibodies that can sometimes be observed years, even decades later. Several studies, some by Bhattacharya and Pepper, have identified antibodies at low levels in the blood months after people recovered from COVID-19.

The antibodies decline, but they settle in what looks like a stable nadir, Bhattacharya said. These have been observed about three months after symptoms show up. The response looks perfectly durable.

Additional studies, including one published in the journal Cell, have isolated T-cells from recovered patients that can attack SARS-CoV-2. In laboratory studies, the T-cells produced signals to fight the virus and cloned themselves in large numbers to fight the potential infection.

This is very promising, said Smita Iyer, an immunologist at the University of California, Davis, who was not involved in the new studies, but has researched immune responses to the novel coronavirus in rhesus macaques. This calls for some optimism about herd immunity, and potentially a vaccine.

It's still has not been definitely determined if milder cases of COVID-19 will lead to long-term or even medium-term immunity. There have been some studies that suggest it does not and some newer studies suggesting it does. Iyer notes that the recent paper indicates, You can still get durable immunity without suffering the consequences of infection.

This idea is reinforced by Eun-Hyung Lee, an immunologist at Emory University who was not involved in these studies. He told The New York Times, Yes, you do develop immunity to this virus, and good immunity to this virus. Thats the message we want to get out there.

Why Seasonal Flu Vaccines Only Last a Year

As most everyone knows, flu vaccines only last about a year. Some of this is related to viral mutations. But in fact, the actual immunity itself caused by the vaccine does not appear to last longer than a year, even though the flu vaccine increases the number of antibody-producing cells specific for the flu in the bone marrow. Researchers out of Emory Vaccine Center found that for most newly-generated plasma cell lineages, between 70 and 99% of the cells were gone after one year, but that the levels of antibody-secreting cells in blood correlated with long-term response in the bone marrow.

Gut Bacteria Can Help Immuno-Oncology Therapies

Researchers with the University of Calgary identified gut bacteria that help our immune system fight cancerous tumors. This also helped provide more information about why immunotherapy works in some cases, but not others. By combining immunotherapy with specific microbial therapy, they believe they can help the immune system and immunotherapy be more effective in treating three types of cancer: melanoma, bladder and colorectal cancers. They found that specific bacteria were essential for immunotherapy to work in colorectal cancer tumors in germ-free mice. The bacteria produced a small molecule called inosine that interacts directly with T-cells and together with immunotherapy.

An Online Calculator to Predict Stroke Risk

Scientists at the University of Virginia Health System developed an online tool that measures the severity of a patients metabolic syndrome, a mix of conditions that includes high blood pressure, abnormal cholesterol levels and excess body fat. With it, they can then predict the patients risk for ischemic stroke. The study discovered that stroke risk increased consistently with metabolic syndrome severity even in patients that did not have diabetes. The tool is available for free at https://metscalc.org/.

A Link Between Autism and Cholesterol

Researchers at Harvard Medical School, Massachusetts Institute of Technology (MIT) and Northwestern University identified a subtype of autism that is the result of a cluster of genes that regulate cholesterol metabolism and brain development. They believe this information can help design precision-targeted therapies for this specific type of autism and improve screening efforts for earlier diagnosis of autism. They analyzed the DNA from brain samples that they then confirmed with the medical records of autistic individuals. They found that children with autism and their parents had significant alterations in lipid blood. However, there is much more to be understood, emphasizing the complexity of autism, which is affected by a variety of genetic and environmental factors.

Researchers Grow First Functioning Mini Human Heart Model

Investigators with Michigan State University grew the first miniature human heart model in the laboratory that is complete with all primary heart cell types and a functioning structure of chambers and vascular tissue. They utilized induced pluripotent stem cells which were obtained from consenting adults and created a functional mini heart in a few weeks. The primary value was in giving them an unprecedented view into how a fetal heart develops.

In the lab, we are currently using heart organoids to model congenital heart diseasethe most common birth defect in humans affecting nearly 1% of the newborn population, said Aitor Aguirre, senior author and assistant professor of biomedical engineering at MSUs Institute for Quantitative Health Science and Engineering. With our heart organoids, we can study the origin of congenital heart disease and find ways to stop it.

Another area of focus is that improving on the final organoid will help with future research. Current heart organoids are not identical yet to human hearts and so are flawed in their use as research models.

See the original post:
Research Roundup: Lasting Immunity to COVID-19 and More - BioSpace

Recommendation and review posted by Bethany Smith

- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration- Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits- G1 launching expanded access program (EAP) for patients with small cell lung cancer in the U.S.

RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for trilaciclib for small cell lung cancer (SCLC) patients being treated with chemotherapy and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2021. Trilaciclib is a first-in-class investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes.

There are currently no available therapies to protect patients from chemotherapy-induced toxicities before they occur, said Raj Malik, M.D., Chief Medical Officer and Senior Vice President, R&D. If approved, trilaciclib would be the first proactively administered myelopreservation therapy that is intended to make chemotherapy safer and reduce the need for rescue interventions, such as growth factor administrations and blood transfusions.

The FDA grants Priority Review to applications for potential therapies that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications.The trilaciclib NDA was supported by compelling myelopreservation data from three randomized, double-blind, placebo-controlled clinical trials in which trilaciclib was administered prior to chemotherapy treatment in patients with SCLC. Trilaciclibhas been granted Breakthrough Therapy Designation by the FDA.In the NDA acceptance letter, the FDA also stated that it is currently not planning to hold an advisory committee meeting to discuss this application.

While undergoing chemotherapy, many patients experience significant myelosuppression, become fatigued and susceptible to infection, and often require transfusions and growth factor administrations, said Jared Weiss, M.D., Lineberger Comprehensive Cancer Center,University of North Carolina Chapel Hill, NC. Preventing bone marrow damage proactively is an opportunity to improve the quality of life of patients receiving chemotherapy for small cell lung cancer and reduce costly rescue interventions.

Myelosuppression is the result of damage to bone marrow stem cells and is one of the most common side effects of chemotherapy. Myelosuppression can lead to serious conditions such as anemia, neutropenia or thrombocytopenia, which have broad ranging clinical, patient experience and economic impacts on ongoing cancer treatment and overall outcomes. In clinical trials, trilaciclib significantly reduced chemotherapy-induced myelosuppression, and patients receiving trilaciclib experienced fewer dose delays/reductions, infections, hospitalizations, and need for rescue therapies compared to patients receiving chemotherapy alone.

Expanded Access ProgramG1 is making trilaciclib available to SCLC patients in the U.S., who are unable to enter clinical trials and for whom there are no appropriate alternative treatments while the trilaciclib NDA is under regulatory review, pursuant to FDAs expanded access program (EAP). To facilitate needed access through the EAP, G1 is collaborating with Bionical Emas, a global specialist clinical research organization (CRO). For more information about the EAP access to trilaciclib, email patient.access.us@Bionical-emas.com.

Complications from myelosuppression have been a long-standing challenge when treating patients with SCLC, said Dr. Malik. Establishing an expanded access program provides qualified patients in serious need with access to trilaciclib while the NDA is under review.

Trilaciclib in Small Cell Lung CancerTrilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. In 2019, trilaciclib received FDA Breakthrough Therapy Designation, and, in June 2020, G1 submitted the NDA based on myelopreservation data from three randomized, double-blind, placebo-controlled clinical trials in which trilaciclib was administered prior to chemotherapy in patients with small cell lung cancer (SCLC). In August 2020, G1 received FDA Priority Review with the Prescription Drug User Fee Act (PDUFA) date of February 15, 2021.

In June 2020, G1 announced a co-promotion agreement with Boehringer Ingelheim for trilaciclib in small cell lung cancer in the U.S. and Puerto Rico. If approved, G1 will lead marketing, market access and medical engagement initiatives for trilaciclib. The Boehringer Ingelheim oncology commercial team, well-established in lung cancer, will lead sales force engagement initiatives.G1 will book revenue and retain development and commercialization rights to trilaciclib and pay Boehringer Ingelheim a promotional fee based on net sales. The three-year agreement does not extend to additional indications that G1 is evaluating for trilaciclib. Press release details of the G1/ Boehringer Ingelheim agreement can be found here.

Evaluating Trilaciclib in Other CancersIn a randomized trial of women with metastatic triple-negative breast cancer, preliminary data showed that trilaciclib improved overall survival when administered in combination with chemotherapy compared with chemotherapy alone. The company plans to present final overall survival data from this trial in the fourth quarter of 2020. Trilaciclib is being evaluated in neoadjuvant breast cancer as part of the I-SPY 2 TRIAL, and the company expects to initiate a Phase 3 trial in patients treated with chemotherapy for colorectal cancer in the fourth quarter of 2020.

About G1 TherapeuticsG1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies: trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy; rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. In 2020, the company out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit http://www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the U.S. and Europe for trilaciclib in SCLC, trilaciclibs possibility to improve patient outcomes across multiple indications, rintodestrants potential to be best-in-class oral SERD, lerociclibs differentiated safety and tolerability profile over other marketed CDK4/6 inhibitors, our reliance on partners to develop and commercial licensed products, and the impact of pandemics such as COVID-19 (coronavirus), are based on the companys expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the companys actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the companys filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the companys ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the companys initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:Investors:Jeff MacdonaldG1 Therapeutics, Inc.Senior Director, Investor Relations & Corporate Communications919-907-1944jmacdonald@g1therapeutics.comMedia:Christine RogersG1 Therapeutics, Inc.Associate Director, Corporate Communications984-365-2819crogers@g1therapeutics.com

Read more from the original source:
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer - GlobeNewswire

Recommendation and review posted by Bethany Smith

New Jersey, United States,- The Stem Cell Therapy Market is predicted by Verified Market Researchs report to find players focusing on new product development to secure a strong position in terms of revenue sharing. Strategic collaboration can be a powerful way to bring new products to the market. The level of competition observed in the market may increase.

This research report categorizes the global market by players/brands, regions, types, and applications. The report also analyzes the global market status, competitive landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, five forces of distributors, and porters.

The latest 2020 edition of this report reserves the right to provide further comments on the latest scenarios, recession, and impact of COVID-19 on the entire industry. It also provides qualitative information on when the industry can rethink the goals the industry is taking to address the situation and possible actions.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Stem Cell Therapy Market Segment Analysis-

The research report includes specific segments by Type and Application. Each type provides information about the production during the forecast period of 2015 to 2027. The application segment also provides consumption during the forecast period of 2015 to 2027. Understanding the segments helps in identifying the importance of different factors that aid market growth.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

The study analyses the following key business aspects:

Analysis of Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the Stem Cell Therapy market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the Stem Cell Therapy market.

Market Forecasts:Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Stem Cell Therapy market.

Regional Growth Analysis:All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis:The report provides accurate and reliable forecasts of the market share of important segments of the Stem Cell Therapy market. Market participants can use this analysis to make strategic investments in key growth pockets of the Stem Cell Therapy market.

Business Opportunities in Following Regions and Countries:

North America (United States, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia, and Australia)

Latin America (Brazil, Argentina, and Colombia)

How will the report assist your business to grow?

The document offers statistical data about the value (US $) and size (units) for the Stem Cell Therapy industry between 2020 to 2027.

The report also traces the leading market rivals that will create and influence the Stem Cell Therapy business to a greater extent.

Extensive understanding of the fundamental trends impacting each sector, although greatest threat, latest technologies, and opportunities that could build the global Stem Cell Therapy market both supply and offer.

The report helps the customer to determine the substantial results of major market players or rulers of the Stem Cell Therapy sector.

Reason to Buy this Report:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global Stem Cell Therapy Market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in Stem Cell Therapy Market, thereby allowing players to develop effective long term strategies.

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Originally posted here:
Stem Cell Therapy Market Size By Product Analysis, By Application, By End-Users, By Regional Outlook, By Top Companies and Forecast to 2027 - Bulletin...

Recommendation and review posted by Bethany Smith

Kyprolis and Velcade have 14 to 16 claims per patient per year for Multiple Myeloma compared to Darzalex and Empliciti which have 9 claims Kyprolis and Velcade have 14 to 16 claims per patient per year for Multiple Myeloma compared to Darzalex and Empliciti which have 9 claims

Want a Demo of Dexur's full capabilities?

Please Enter Your Name and Email Addess

Please Enter Your Name

Please Enter Your Email Addess

By: Sruthy Iype  Aug. 20, 2020

Dexurs analysis of Medicare claims data showed that on an average, Kyprolis and Velcade have 14 to 16 claims per patient per year for Multiple Myeloma (MM) compared to Darzalex and Empliciti which have 9 claims per patient. The analysis was based on a sample of Medicare patients between Jan 2019 and Dec 2019, and looked at the J code usage of the drugs for the condition.The number of claims per patient data is a proxy for the number of injections / IV infusions / doses required by a patient. The study also tries to contrast the usage of these medications across three diagnosis categories- MM patients who have not achieved remission (C9000), MM patients in remission (C9001), and MM patients in relapse (C9002).

Multiple myeloma is a form of blood cancer that involves the neoplastic proliferation of plasma cells, a type of white blood cells formed within the bone marrow. While the earlier stages of the disease tend to be asymptomatic, patients may experience symptoms like bone pain, bleeding, frequent infections, and anemia with progression of the cancer. Although there is no cure for MM, a number of treatment options including chemotherapy, stem cell transplantation, radiation therapy, and targeted therapy, can help in managing the progression of the disease and relieving the symptoms.

The drugs considered under this study are targeted therapies approved for the treatment of adult patients with multiple myeloma, alone or in combination with other medication. Unlike chemotherapy, these drugs specifically target the cancer cells and the mechanisms that support their growth, promising better results and fewer adverse effects. Kyprolis (carfilzomib) and Velcade (bortezomib) are proteasome inhibitors that can trigger apoptosis in cancer cells by blocking the action of proteasome, an enzyme complex that is critical in the regulation of cell-cycle. Darzalex (daratumumab) and Empliciti (elotuzumab) are monoclonal antibodies that enable the immune system to identify and kill cancer cells by targeting specific proteins on the cell surface.

The average usage of drug per patient was seen to be highest among MM patients who had not achieved remission, and least among MM patients in remission. An exception to this trend was Kyprolis, which had similar usage among patients in remission and patients in relapse, with the former having a marginally higher number of claims per patient.

Amgens Kyprolis had an average of 15.9 claims per patient in a year. The proteasome inhibitor indicated for the treatment of patients with relapsed/refractory MM, is used as a monotherapy, or as a combination therapy along with dexamethasone, or lenalidomide and dexamethasone.

Velcade, manufactured by Millennium Pharmaceuticals/Takeda Oncology in the U.S, had an average of 13.8 claims per patient in a year. It was noted to have the largest share of claims among the drugs, across the three diagnosis categories for multiple myeloma. Approved for the treatment of newly diagnosed and relapsed/refractory myeloma, the drug is used alone or as a part of combination therapies.

Darzalex, a CD38-directed cytolytic antibody by Janssen Biotech, had an average of 9.9 claims per patient in a year for MM. It is indicated for the treatment of MM as a monotherapy or in combination with other drugs including lenalidomide, dexamethasone, and bortezomib.

Bristol-Myers Squibbs Empliciti had an average of 9.3 claims per patient. It is a SLAMF7-directed immunostimulatory antibody approved for the treatment of MM in combination with lenalidomide and dexamethasone, or pomalidomide and dexamethasone

Excerpt from:
Kyprolis and Velcade have 14 to 16 claims per patient per year for Multiple Myeloma compared to Darzalex and Empliciti which have 9 claims - Dexur

Recommendation and review posted by Bethany Smith

Copenhagen, Denmark; August 20, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX (daratumumab) in combination with carfilzomib and dexamethasone (DKd) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy. A supplemental Biologics License Application (sBLA) for this indication was submitted by Genmabs licensing partner, Janssen Biotech, Inc. (Janssen), in February 2020. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

We are extremely pleased that multiple myeloma patients in the U.S. will now have yet another treatment option as this is the eighth overall U.S. FDA approval for DARZALEX and the fifth in the relapsed/refractory setting. In addition, DARZALEX is now the first CD38 antibody approved for use in combination with carfilzomib, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The combination has been approved in two carfilzomib dosing regimens, 70 mg/m2 once weekly and 56 mg/m2 twice weekly, based on positive results from the Phase 3 CANDOR and Phase 1b EQUULEUS studies. CANDOR was an Amgen-sponsored study, co-funded by Janssen Research & Development, LLC. EQUULEUS was sponsored by Janssen Research & Development, LLC.

About the CANDOR studyThe Phase 3 trial (NCT03158688) was a randomized, open-label study that included 466 patients with multiple myeloma who had relapsed after 1 to 3 prior therapies. Patients were randomized to receive either DKd or carfilzomib and dexamethasone (Kd) alone. In the daratumumab treatment arm, patients received 8 milligrams per kilogram (mg/kg) on days 1 and 2 of cycle 1, then 16 mg/kg once weekly for the remaining doses of the first 2 cycles, then every 2 weeks for 4 cycles (cycles 3 to 6), and then every 4 weeks for the remaining cycles or until disease progression. In both treatment arms carfilzomib was dosed twice weekly (20 mg/m2 on cycle 1 days 1 and 2 and 56 mg/m2 beginning on cycle 1 day 8 and thereafter) and dexamethasone was given weekly (40 mg orally or via IV infusion). The primary endpoint of the study was progression free survival (PFS).

About the EQUULEUS (MMY1001) Study The Phase 1b EQUULEUS (NCT01998971) study was an open label, multi-cohort trial that evaluated the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma. Among the regiments evaluated, the combination of DKd compared to Kd alone was studied in 85 patients with relapsed/refractory multiple myeloma who had received one to three prior lines of therapy using a once-weekly dosing regimen. DKd was evaluated at a starting dose of 20 mg/m2, which was increased to 70 mg/m2 on Cycle 1, Day 8 and onward.

About multiple myelomaMultiple myeloma is an incurable blood cancer that starts in the bone marrow and is characterized by an excess proliferation of plasma cells.1 Multiple myeloma is the third most common blood cancer in the U.S., after leukemia and lymphoma.2 Approximately 26,000 new patients were expected to be diagnosed with multiple myeloma and approximately 13,650 people were expected to die from the disease in the U.S. in 2018.3 Globally, it was estimated that 160,000 people were diagnosed and 106,000 died from the disease in 2018.4 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms which can include bone problems, low blood counts, calcium elevation, kidney problems or infections.5

About DARZALEX (daratumumab)DARZALEX (daratumumab) has become a backbone therapy in the treatment of multiple myeloma. DARZALEX intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with carfilzomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received one to three previous lines of therapy; in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.6 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy7. Daratumumab is the first subcutaneous CD38 antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.8 DARZALEX FASPRO is the first subcutaneous CD38 antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).6,9,10,11,12

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of the following approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Kesimpta (subcutaneous ofatumumab, under agreement with Novartis AG), for the treatment of adults with relapsing forms of multiple sclerosis in the U.S. and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in the U.S., has been approved in the U.S. and Europe for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy, Arzerra (ofatumumab, under agreement with Novartis AG), approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Continue reading here:
Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX (daratumumab) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refrac...

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Marketis expected to reach 202.77 billion by 2026 from XX billion in 2018 at CAGR of XX %.REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/522

Stands for use of stem cells to treat or prevent disease or condition.Bone marrow transplant and some therapies derived from umbilical cord blood are mainly used in stem cell therapy. Advancement, in order to establish new sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions such as diabetes, heart disease, and other conditions, are increased in recent years.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Stem Cell Therapy Market Researchers are making efforts to discover novel methods to create human stem cells. This will increase the demand as well as supply for stem cell production and potential investigation in disease management. Increasing investment & research grants for developing safe and effective stem cell therapy products, the growing patient base for target diseases, concentrated product pipelines, increasing approval of the new clinical trials, rapid technological advancement in genomics, and the rising awareness about the stem cell are expected to drive the growth of the Stem Cell Therapy solutions market during the forecast period.

However, improper infrastructure, insufficient storage systems, nascent technology in underdeveloped economies, Ethical issues related to an embryonic stem cell, low patient acceptance rate, Difficulty in the preservation of stem cell are expected to restrain the market growth. North America is expected to be the largest growing region by 2026; the reason behind that is extensive funding by Government. However, Emerging countries like India, china, Korea have low growth rate as compared to Developed regions in 2017 but increase in awareness about stem cell therapy will lead the Asia Pacific to generate a significant level of revenue by 2026.

Key Highlights of Stem Cell Therapy Market report

Detailed quantitative analysis of the current and future trends from 2017 to 2026, which helps to identify the prevailing market opportunities.Comprehensive analysis of factors instrumental in changing the market scenario, rising prospective opportunities, market shares, core competencies in terms of market development, growth strategies and identification of key companies that can influence this market on a global and regional scale.Assessment of Market definition along with the identification of key drivers, restraints opportunities and challenges for this market during the forecast period.Complete analysis of micro-markets with respect to individual growth trends, prospects, and contributions to the overall Stem Cell Therapy Solutions market.Stem Cell Therapy market analysis and comprehensive segmentation with respect to the Application, End users, Treatment, and geography to assist in strategic business planning.Stem Cell Therapy market analysis and forecast for five major geographies-North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and their key regions.For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered.

Research Methodology:

The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at a global market value for the stem cell therapy market.Key Players in the Stem Cell Therapy Market are:

Chiesi Farmaceutici S.P.A Are:Gamida CellReNeuron Group, plcOsiris Therapeutics, Inc.Stem Cells, Inc.Vericel Corporation.Mesoblast, Ltd.

Key Target Audience:

Stem Cell Associations and OrganizationsGovernment Research Boards and OrganizationsResearch and consulting firmsStem Cell Therapy Market InvestorsHealthcare Service Providers (including Hospitals and Diagnostic Centers)Stem Cell Therapeutic Product Manufacturing OrganizationsResearch LabsClinical research organizations (CROs)Stem Cell Therapy Marketing PlayersPharmaceutical Product Manufacturing CompaniesScope of the Stem Cell Therapy Market Report:

Stem Cell Therapy market research report categorizes the Stem Cell Therapy market based on Application, End users, Treatment, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Stem Cell Therapy market with key developments in companies and market trends.Stem Cell Therapy Market, By Treatments:

Allogeneic Stem Cell TherapyAutologous Stem Cell Therapy

Stem Cell Therapy Market, By End Users:

HospitalsAmbulatory Surgical Centers

Stem Cell Therapy Market, By Application:

OncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, By Geography:

North AmericaEuropeAsia PacificMiddle East & AfricaLatin America

Available Customization:

With the given market data, Maximize Market Research offers customization of report and scope of the report as per the requirement

Regional Analysis:

Breakdown of the North America stem cell therapy marketBreakdown of the Europe stem cell therapy marketBreakdown of the Asia Pacific stem cell therapy marketBreakdown of the Middle East & Africa stem cell therapy marketBreakdown of the Latin America stem cell therapy market

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/stem-cell-therapy-market/522/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

See the rest here:
Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Good Night, Good Hockey

Recommendation and review posted by Bethany Smith

A new market report by The Insight Partners on the Cell Therapy Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies. Hence, this research study serves as an important depository of the information for every market landscape. The report is segmented on the basis of types, end-users, applications, and regional markets.

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is used to treat a variety of blood cancers and blood-related conditions.

Get Sample PDF of at: https://www.theinsightpartners.com/sample/TIPRE00009666/

Key companies Included in Cell Therapy Market:-

Kolon TissueGene, Inc. MEDIPOST JCR Pharmaceuticals Co. Ltd. Stemedica Cell Technologies, Inc. Osiris Therapeutics, Inc. NuVasive, Inc. Fibrocell Science, Inc. Vericel Corporation Cells for Cells Celgene Corporation

The global cell therapy market is segmented on the basis of therapy type, product, technology, application, end user. Based on the therapy type the market is classified as autologous, and allogeneic. Based on product the market is segmented as equipment, consumables, software and services. Based on technology the market is segmented as somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Based on application the market is classified as oncology, cardiology, orthopedic, wound management and others. And based on end user the market is divided into hospitals, regenerative medicine centers, and research institutes.

The report offers key drivers that propel the growth in the global Cell Therapy Market. These insights help market players in devising strategies to gain market presence. The research also outlined the restraints of the market. Insights on opportunities are mentioned to assist market players in taking further steps by determining the potential in untapped regions.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Cell Therapy Market which would mention How the Covid-19 is Affecting the Disposable Incontinence Products (DIPs) Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Disposable Incontinence Products (DIPs) Players to fight Covid-19 Impact.

Cell Therapy Market: Regional analysis includes:

Owning our reports will help you solve the following issues:

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 10+ companies.

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00009666/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact:

Call: +1-646-491-9876

Email: [emailprotected]

Here is the original post:
Cell Therapy Market Opportunities, Threats, Trends, Applications, And Growth Forecast To 2027 | MEDIPOST, Osiris Therapeutics, NuVasive, Cells for...

Recommendation and review posted by Bethany Smith

The research study on Global Cell Therapy Manufacturing market 2019 presents an extensive analysis of current Cell Therapy Manufacturing market size, drivers, trends, opportunities, challenges, as well as key Cell Therapy Manufacturing market segments. Further, it explains various definitions and classification of the Cell Therapy Manufacturing industry, applications, and chain structure.In continuation of this data, the Cell Therapy Manufacturing report covers various marketing strategies followed by key players and distributors. Also explains Cell Therapy Manufacturing marketing channels, potential buyers and development history. The intent of global Cell Therapy Manufacturing research report is to depict the information to the user regarding Cell Therapy Manufacturing market forecast and dynamics for the upcoming years.The Cell Therapy Manufacturing study lists the essential elements which influence the growth of Cell Therapy Manufacturing industry. Long-term evaluation of the worldwide Cell Therapy Manufacturing market share from diverse countries and regions is roofed within the Cell Therapy Manufacturing report. Additionally, includes Cell Therapy Manufacturing type wise and application wise consumption figures.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225722

After the basic information, the global Cell Therapy Manufacturing Market study sheds light on the Cell Therapy Manufacturing technological evolution, tie-ups, acquisition, innovative Cell Therapy Manufacturing business approach, new launches and Cell Therapy Manufacturing revenue. In addition, the Cell Therapy Manufacturing industry growth in distinct regions and Cell Therapy Manufacturing R&D status are enclosed within the report.The Cell Therapy Manufacturing study also incorporates new investment feasibility analysis of Cell Therapy Manufacturing. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Cell Therapy Manufacturing market.

View Source of RelatedReports :

Cell Therapy Manufacturing Market

Cell Cryopreservation Market

Botanical And Plant-Derived Drugs Market

Alopecia Treatment Market

Advanced Wound Care Market

Global Cell Therapy Manufacturing Market Segmentation 2019:The study also classifies the entire Cell Therapy Manufacturing market on basis of leading manufacturers, different types, various applications and diverse geographical regions.Overall Cell Therapy Manufacturing market is characterized by the existence of well-known global and regional Cell Therapy Manufacturing vendors. These established Cell Therapy Manufacturing players have huge essential resources and funds for Cell Therapy Manufacturing research as well as developmental activities. Also, the Cell Therapy Manufacturing manufacturers focusing on the development of new Cell Therapy Manufacturing technologies and feedstock. In fact, this will enhance the competitive scenario of the Cell Therapy Manufacturing industry.

The Leading Players involved in global Cell Therapy Manufacturing market are:harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Based on Therapy Type, the Cell Therapy Manufacturing market is categorized into: Allogeneic Cell Therapy Autologous Cell Therapy

Based on Technology, the Cell Therapy Manufacturing market is categorized into: Somatic Cell Technology Cell Immortalization Technology Viral Vector Technology Genome Editing Technology Cell Plasticity Technology 3D Technology

Based on Source, the Cell Therapy Manufacturing market is categorized into: IPSCs Bone Marrow Umbilical Cord Adipose Tissue Neural Stem Cells

Based on Application, the Cell Therapy Manufacturing market is categorized into: Musculoskeletal Cardiovascular Gastrointestinal Neurological Oncology Dermatology Other

Global Cell Therapy Manufacturing Market Regional Analysis:The companies in the world that deals with Cell Therapy Manufacturing mainly concentrate following regions.North America, Europe, Asia Pacific, Latin America, and Middle East & AfricaGlobal Cell Therapy Manufacturing Industry Report Covers following Topics:01: Cell Therapy Manufacturing Market Overview02: Global Cell Therapy Manufacturing Sales, Revenue (value) and Market Share by Players03: Cell Therapy Manufacturing Market Sales, Revenue (Value) by Regions, Type and Application (2014-2018)04: Region wise Top Players Cell Therapy Manufacturing Sales, Revenue and Price05: worldwide Cell Therapy Manufacturing Industry Players Profiles/Analysis06: Cell Therapy Manufacturing Cost Analysis07: Industrial Chain, Cell Therapy Manufacturing Sourcing Strategy and Downstream Buyers08: Cell Therapy Manufacturing Marketing Strategy Analysis, Distributors/Traders09: Cell Therapy Manufacturing Industry Effect Factors Analysis10: Global Cell Therapy Manufacturing Market Forecast (2019-2026)11: Cell Therapy Manufacturing Research Findings and Conclusion12: Appendix

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225722

Worldwide Cell Therapy Manufacturing Market Different Analysis:Competitors Review of Cell Therapy Manufacturing Market: Report presents the competitive landscape scenario seen among top Cell Therapy Manufacturing players, their company profile, revenue, sales, business tactics and forecast Cell Therapy Manufacturing industry situations.Production Review of Cell Therapy Manufacturing Market: It illustrates the production volume, capacity with respect to major Cell Therapy Manufacturing regions, application, type, and the price.

Sales Margin and Revenue Accumulation Review of Cell Therapy Manufacturing Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Cell Therapy Manufacturing target consumer.

Supply and Demand Review of Cell Therapy Manufacturing Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Cell Therapy Manufacturing product type. Also interprets the Cell Therapy Manufacturing import/export scenario.

Other key reviews of Cell Therapy Manufacturing Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Cell Therapy Manufacturing players, potential consumers and suppliers. Also, the strengths, opportunities, Cell Therapy Manufacturing market driving forces and market restraints are studied in this report.

Highlights of Global Cell Therapy Manufacturing Market Report:* This report provides in detail analysis of the Cell Therapy Manufacturing and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 2029.* It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Cell Therapy Manufacturing market.* This study also provides key insights about Cell Therapy Manufacturing market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Cell Therapy Manufacturing players.* It profiles leading players in the worldwide Cell Therapy Manufacturing market based on the following parameters company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.* Insights from Cell Therapy Manufacturing report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Cell Therapy Manufacturing marketing tactics.* The world Cell Therapy Manufacturing industry report caters to various stakeholders in Cell Therapy Manufacturing market. That includes investors, device manufacturers, distributors and suppliers for Cell Therapy Manufacturing equipment. Especially incorporates government organizations, Cell Therapy Manufacturing research and consulting firms, new entrants, and financial analysts.*Various strategy matrices used in analyzing the Cell Therapy Manufacturing market would provide stakeholders vital inputs to make strategic decisions accordingly.Global Cell Therapy Manufacturing Market Report Provides Comprehensive Analysis of Following: Cell Therapy Manufacturing Market segments and sub-segments Industry size & Cell Therapy Manufacturing shares Cell Therapy Manufacturing Market trends and dynamics Market Drivers and Cell Therapy Manufacturing Opportunities Supply and demand of world Cell Therapy Manufacturing industry Technological inventions in Cell Therapy Manufacturing trade Cell Therapy Manufacturing Marketing Channel Development Trend Global Cell Therapy Manufacturing Industry Positioning Pricing and Brand Strategy Distributors/Traders List enclosed in Positioning Cell Therapy Manufacturing Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225722

Moreover, the report organizes to provide essential information on current and future Cell Therapy Manufacturing market movements, organizational needs and Cell Therapy Manufacturing industrial innovations. Additionally, the complete Cell Therapy Manufacturing report helps the new aspirants to inspect the forthcoming opportunities in the Cell Therapy Manufacturing industry. Investors will get a clear idea of the dominant Cell Therapy Manufacturing players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Originally posted here:
Cell Therapy Manufacturing Market 2020 Report Including COVID-19 Impact Analysis and Forecast till 2029 - Scientect

Recommendation and review posted by Bethany Smith

Major Players in This Report Include: Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

CMI released a new market study covering the current COVID-19 impact on the Global Orthopedic Regenerative Medicine Market with detailed insights on latest scenario, economic slowdown on overall industry. This report will help you to identify which types of companies could potentially benefit from the impact of COVID-19, as well as those business segments that are set to lose out.

The competition is expected to become even more intense in the coming years with the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the markets competitive landscape and offers information on the products offered by various leading companies. Additionally, this Orthopedic Regenerative Medicine market analysis report suggests strategies Vendors can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

Definition:

Orthopedic Regenerative Medicine strategy sends messages to the customers or subscribers in predefined schedule. However, other forms of media can also be used in Orthopedic Regenerative Medicine. It is the most common form of marketing as multiple messages can be sent in low costs. Orthopedic Regenerative Medicine is used to achieve business objectives such as increasing sales, maintaining communications with customers while saving the business time. Moreover, the users can personalize each of the email messages and increase conversion rate.

Market Drivers

Market Trend

Opportunities

Challenges

Detailed Segmentation:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get Free Download PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/3566

Strategic Points Covered in Table of Content of Global Orthopedic Regenerative Medicine Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Orthopedic Regenerative Medicine market

Chapter 2: Exclusive Summary the basic information of the Orthopedic Regenerative Medicine Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Orthopedic Regenerative Medicine

Chapter 4: Presenting the Orthopedic Regenerative Medicine Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2014-2020

Chapter 6: Evaluating the leading manufacturers of the Orthopedic Regenerative Medicine market which consists of its Competitive Landscape, Peer Group Analysis

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Orthopedic Regenerative Medicine Market is a valuable source of guidance for individuals and companies in decision framework.

What benefits does CMI research study is going to provide?

Get Discount on This Premium Report @https://www.coherentmarketinsights.com/insight/request-discount/3566

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

Mr Raj ShahCoherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone +1-206-701-6702[emailprotected]

View post:
Orthopedic Regenerative Medicine Market 2020-2027 COVID-19 Pandemic Analysis and forecast to 2027 | Curasan, Inc., Carmell Therapeutics Corporation,...

Recommendation and review posted by Bethany Smith

Patient enrollment to commence immediately

VANCOUVER, Washington, Aug. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn” or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the Clinical Trials Unit of the Medicines & Healthcare product Regulatory Agency (MHRA) of the U.K. government authorized the Company to enroll for its ongoing Phase 3 COVID-19 trial for severe-to-critical patients in the United Kingdom. The MHRA’s decision follows several months of its review of CytoDyn’s manufacturing processes and leronlimab’s safety profile.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, We are very pleased with the MHRA’s confidence in leronlimab to initiate enrollment of patients in the U.K. for our current CD12 protocol. CytoDyn recently requested fast track approval” from the MHRA for its completed Phase 2 COVID-19 trial for the mild-to-moderate population, with strong efficacy and safety data. We believe leronlimab has multiple opportunities for several clinical indications and we are very optimistic about our future based upon how far we have advanced this drug in about 5 years. In addition, we plan to file a BLA for HIV in the U.K. within the next 4 weeks.”

About Coronavirus Disease 2019 CytoDyn completed its Phase 2 clinical trial (CD10) for COVID-19, a randomized clinical trial for mild-to-moderate patients in the U.S. Enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 is believed to typically transmit person-to-person through respiratory droplets. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for critical illnesses. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug” designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH.

CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The FDA has agreed to provide written responses to the Company’s questions concerning its recent Biologics License Application by September 4, 2020, in lieu of a Type A teleconference meeting for this HIV combination therapy.

CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years.

CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes,” hopes,” intends,” estimates,” expects,” projects,” plans,” anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS Investors: Michael Mulholland Office: 360.980.8524, ext. 102 Mobile: 503.341.3514 mmulholland@cytodyn.com

See the original post here:
After Several Months of Providing Requested Information About Manufacturing and Safety of Leronlimab, U.K.'s MHRA Accepts CytoDyn's Request to Enroll...

Recommendation and review posted by Bethany Smith

PORT HOPE, ON, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Cameco and Bruce Power announced today a series of initiatives highlighted by the creation of a centre for next generation nuclear technologies to leverage their existing partnership to help restart the Canadian economy, protect the environment and fight diseases like COVID-19 around the world. In addition, further to the Bruce Power Life-Extension Program and the existing long-term supply agreement, Cameco and Bruce Power have announced the additional supply of 1,600 specialized fuel bundles for Unit 6 scheduled for restart in 2024.

The two companies are industry leaders in Ontario, Saskatchewan and Canada, directly and indirectly employing 27,000 workers and creating $9-12 billion of investment annually in the Canadian economy. Bruce Power, Cameco and the entire Canadian nuclear industry remain at the forefront of science and innovation in the production of GHG emissions-free power and cancer-fighting isotopes.

Throughout the pandemic, Bruce Power and Cameco have been able to ensure the safe and reliable supply of GHG emissions-free electricity to millions of people in Canada, and will now leverage one of Canadas largest infrastructure projects, the Bruce Power Life-Extension Program, to help rebuild the national economy through innovation, including exploring project acceleration and other opportunities.

To expand on their important inter-provincial partnership, as founding members of the Nuclear Innovation Institute (NII), Bruce Power and Cameco are proud to announce the launch of the NII Centre for Next Generation Nuclear Technologies to identify post-COVID economic, environmental and health-care opportunities.

The new centre will focus on next generation nuclear technologies by advancing the existing expertise of suppliers, regulators and operators to support future economic, environmental and export opportunities for Ontario, Saskatchewan and beyond. Innovations in nuclear energy will help support new technologies like small modular reactors (SMRs), cancer-fighting isotopes and hydrogen development by using infrastructure investments that will drive the economy now and power the world of the future. It will also look at how the current Bruce Power site output can be further enhanced with new technologies and as foundational enablers.

Todays announcement, along with the existing long-term arrangements between Bruce Power and Cameco, opens the door to assist the provincial governments in both Saskatchewan and Ontario with getting the economy back on its feet after six difficult months working to protect and keep people safe in both provinces, said Mike Rencheck, President and CEO of Bruce Power. Were extremely grateful to Premiers Ford and Moe, and the members of their respective governments, for realizing the positive impact that the nuclear industry has on the lives of Canadians.

Our focus, through the Centre, on next generation nuclear technology is anchored on the basis of building from our existing assets including life extension and efficiencies, partnerships and supply chain. This has the potential to fully leverage existing assets, reducing the need for more costly new generation in the future, creating a foundation for new medical isotopes and a hydrogen economy all while laying the foundation for new nuclear such as SMRs.

Cameco and Bruce Power will also be expanding their role in support of the production of life-saving medical isotopes. With its facility in Cobourg, ON, Cameco will contribute its expertise to the development of Bruce Powers new Isotope Production System being developed by its partner IsoGen that will help produce Lutetium-177, an isotope used to treat prostate cancer and neuroendocrine tumors. Bruce Power aims to begin harvesting Lutetium-177 in 2022. Cameco is a key supplier of materials in the production of Cobalt-60, which is produced in partnership with Ottawa-based Nordion, used to sterilize medical equipment and treat breast cancer and brain tumours.

Medical isotopes and leveraging our existing infrastructure in a post-COVID world are an important part of the future of nuclear, and Bruce Power is a leader and innovator in this sector, said Tim Gitzel, president and CEO of Cameco. I am proud that Cameco is able to contribute to this important work, especially now when the need for sterilized medical supplies is so high.

Were pleased to have our Ontario and Saskatchewan Premiers join us in celebrating our announcement today as the strength of the nuclear industry is grounded in meaningful relationships across the industry and across provinces..

Through their work on the Retooling and Economic Recovery Council, Bruce Power and Cameco focused on helping to ensure their communities had the tools they needed to endure the pandemic and now the focus has turned to powering the recovery.

The Life-Extension Program will continue to be a key economic driver and today will see a new arrangement for start-up fuel to be provided by Cameco when Bruce Powers nuclear reactors are ready to return to service following Major Component Replacement, beginning with the Unit 6 reactor. Cameco will supply 1,600 specialized fuel bundles for the safe restart of Unit 6, scheduled for 2024. This builds on the existing fuel arrangements between the two organizations announced in 2017 which was estimated to be worth $2 billion at the time and over the life of the contracts.

This new initiative will help drive Ontario-made and Canadian-made innovation for these emerging technologies and support our provinces economic recovery, said Ontario Premier Doug Ford. I want to thank Bruce Power and Cameco for this important investment, as well as for their generous community and PPE donations to support our front-line heroes and those in need over the past few months.

Working together, we will ensure our communities can recover and our economy can come roaring back.

Saskatchewan Premier Scott Moe also offered his praise for the strong partnership.

The announcement today from Cameco and Bruce Power underscores the importance of Canadas nuclear industry, which is world class in every respect, from mining to research to power production, said Premier Moe. In Saskatchewan, were grateful for the contributions Cameco and Bruce Power are making every day to Canadas economic and social well-being.

About Cameco

Cameco is one of the largest global providers of the uranium fuel needed to energize a clean-air world. Our competitive position is based on our controlling ownership of the worlds largest high-grade reserves and low-cost operations. Utilities around the world rely on our nuclear fuel products to generate power in safe, reliable, carbon-free nuclear reactors. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan.

About Bruce PowerFormed in 2001, Bruce Power is an electricity company based in Bruce County, Ontario. We are powered by our people. Our 4,200 employees are the foundation of our accomplishments and are proud of the role they play in safely delivering clean, reliable, low-cost nuclear power to families and businesses across the province. Bruce Power has worked hard to build strong roots in Ontario and is committed to protecting the environment and supporting the communities in which we live. Learn more atwww.brucepower.comand follow us onFacebook,Twitter,LinkedIn,InstagramandYouTube.

Continued here:
Cameco and Bruce Power support launch of Centre for Next Generation Nuclear Technologies and announce contracts that support innovation and isotope...

Recommendation and review posted by Bethany Smith

SYDNEY, Aug. 19, 2020 /PRNewswire/ --The Silverfern Group, an investment management firm making direct investments in middle market private equity globally, today announced thatit has partnered with Next Capital in the acquisition of Eptec ("Eptec").

Eptec, founded in 1997, is an Australian-based specialist engineering contractor focused on asset preservation and maintenance services to the marine sector (defense and commercial) and other critical transport and infrastructure assets.

"We are excited to partner with Next Capital in the acquisition of Eptec, a leading specialist engineering contractor in the Australian market," said Silverfern Managing Partner Clive Holmes."Silverfern Advisory Board member Geoff Knox, an experienced senior Eptec executive, has helped us evaluate the Eptec investment opportunity and has stepped up to the role of CEO upon completion of the acquisition. The acquisition of Eptec further demonstrates Silverfern's ability to source, access and execute on attractive stable local investments, even during challenging economic times such as the COVID-19 pandemic, as we continue to invest on a global basis."

About EptecFounded in 1997 Eptec has a 22-year track record providing asset preservation and maintenance services to government and prime corporate clients. Eptec delivers time-critical, highly-technical, specialized asset life extension of complex operational assets through a range of solutions for Corrosion Protection, Concrete Rehabilitation, Fibre Reinforced Plastics, Waterproofing and Linings, and Insulation, and operates through two business segments: Marine and Services. The Marine business segment services defense and commercial sectors and the Services business segment services transportation infrastructure (including bridges, rail and ports), energy and resources, waste and wastewater, and buildings and facilities. https://eptec.com.au

About SilverfernSilverfern is a global middle-market investment management firm. From its offices in New York, Amsterdam, Frankfurt and Sydney, its experienced, cohesive team of senior investment professionals makes investments in global middle-market private equity. Targeting $25 million to $50 million equity per investment in partnership with qualified local investment partners, whom we select for their specific industry knowledge and local market experience, Silverfern seeks to invest in buyouts, build-ups, acquisitions, growth equity and recapitalizations worldwide. Silverfern's investment strategy seeks to mitigate systemic risk in its portfolio by opportunistically pursuing attractive risk-adjusted returns on a global basis, while at the same time seeking to manage local/market risk through its strategy to partner with qualified, local, investment partners on each of its investments. Silverfern is currently investing from Silverfern Global Opportunities Fund III. Additional information is available at http://www.silfern.com

Media Contacts: Robert SpittlerSilverfern[emailprotected]+49 173 25 37 465

SOURCE The Silverfern Group

Home

See the original post here:
The Silverfern Group Invests in Eptec, in Partnership with Next Capital - PRNewswire

Recommendation and review posted by Bethany Smith

While the vast array of shelf life extension technology for fresh cut produce has grown exponentially over the last decade, strawberries had been absent from the list until recently. This highly popular and beloved berry had eluded efforts to extend its shelf life after cutting.

Through focused research and development, NatureSeal has succeeded in creating a treatment to maintain the fresh qualities of cut strawberries. This newly introduced product is a healthy, clean-label powder blend that protects sliced, topped, halved and diced fresh strawberries, maintaining freshness for up to eleven days when refrigerated. NatureSeal retards spoilage and maintains the color and firmness of fresh-cut strawberries without altering flavor.

NatureSeal ST-A is comprised of GRAS ingredients and is allergen-free, gluten-free, Kosher certified and non-GMO.

The NatureSeal for strawberry product is easy to use and perfect for cut fruit medleys, yogurt and baked goods toppings or as a stand-alone offering.

For more information:Tim Grady NatureSeal, Inc.Tel: 203-767-0059Email: Tim.Grady@natureseal.comwww.natureseal.com

Read more from the original source:
'Maintaining the fresh qualities of cut strawberries' - hortidaily.com

Recommendation and review posted by Bethany Smith

MINSK, 19 August (BelTA) Nuclear energy meets all requirements of the energy industry of the future, BelTA learned from Artyom Petrosyan, Acting Director General of ZAO Scientific Research Institute of Energy (SRIE), Candidate of Science (Engineering).

According to the source, electricity consumption is rising fast all over the world and is expected to rise by 28-32% by 2040. Virtually all the countries have undertaken to reduce carbon dioxide emissions within the framework of the Paris Climate Agreement. It is possible to honor the commitment while increasing the use of electricity only if the structure of the global balance of electricity generation changes.

Artyom Petrosyan believes that requirements for the energy industry of the future can be determined as follows: the cost of energy should be economically attractive and stable over a lengthy period of time, the method of energy generation should be environmentally friendly.

The expert believes that nuclear energy industry meets these requirements. At the same time nuclear energy is not an alternative to other environmentally friendly sources of electricity. Solar power, wind power, water power, and nuclear power should complement each other and produce the foundation of the future global carbon-free balance.

Just like Belarus Armenia has no oil and natural gas of its own. For many nations nuclear energy represents a tried-and-tested, clean, safe, and economical technology that will play an important role in achieving energy security and sustainable development goals in the 21st century, Artyom Petrosyan noted.

The second unit of the Armenian nuclear power plant generates about 40% of the electricity the country uses. The nuclear power plant does not need continuously imported natural gas. The nuclear power plant releases no greenhouse gases and provides a steady source of electricity for households and the manufacturing sector. Taking into account these factors, the Armenian government has decided to extend the designed service life of the second unit of the Armenian nuclear power plant. In December 2014 Armenia and Russia signed an intergovernmental agreement on cooperation in extending the designed service life of the second unit of the Armenian nuclear power plant. An intergovernmental agreement on financing the service life extension program was signed in 2015. A colossal amount of work is supposed to be done on a tight schedule within the framework of the project.

Artyom Petrosyan is convinced that the future of the world nuclear energy industry belongs to the closed nuclear fuel cycle. If the fuel cycle is closed, nuclear energy will become even more environmentally friendly and safer. It will offer a virtually inexhaustible source of energy for millennia. Taking into account the current level of science and technology there are reasons to believe that an integrated product will be offered to the international market within the next 10-15 years, the expert believes. In his opinion, the creation of the industrial infrastructure able to reduce the number of spent nuclear fuel storage facilities and recycle spent nuclear fuel components is the key task.

The expert believes that international cooperation will play a prominent role in the future. First of all, we are talking about safety. We should definitely support efforts of the International Atomic Energy Agency to consistently raise requirements in this field. The world nuclear energy industry demonstrates impeccable dedication to principles of safe and steady development of all spheres of the manufacturing sector. Safe technologies and solutions are not just a requirement, but the crucial condition for any nuclear project, Artyom Petrosyan stressed.

The expert identified the coordination of efforts to shape the correct reputation of the nuclear energy industry as the second direction of international cooperation. We should step up cooperation in order to not just simply form public acceptability of nuclear energy but enable conditions for public need for nuclear energy, he noted.

According to the source, the key role of the nuclear energy industry is to enable steady development and global transition to low-carbon types of electricity generation. Nuclear energy meets all the requirements of the energy industry of the future, Artyom Petrosyan stressed.

Excerpt from:
Expert: Nuclear energy meets all requirements of the energy industry of the future | SCIENCE. TECHNOLOGY. INNOVATIONS | NPP Belarus Nuclear power...

Recommendation and review posted by Bethany Smith